UK firm declares positive results from COVID-19 protein treatment
London: A UK-based biotech company on Monday declared positive "breakthrough" results from a clinical trial of a protein-based treatment for COVID-19, which "greatly" reduced patients requiring intensive care.
Synairgen said its SNG001 formulation uses a protein called interferon beta, which the body produces when it gets a viral infection, and is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.
"This assessment of SNG001 in COVID-19 patients could signal a major breakthrough in the treatment of hospitalised COVID-19 patients, said Richard Marsden, CEO of Synairgen, a respiratory drug discovery and development company which originated from research at the University of Southampton.
We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from requiring oxygen' to requiring ventilation'. It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2 (COVID-19), he said.
In addition, SNG001 significantly reduced breathlessness, one of the main symptoms of severe COVID-19, the company said, which is now focused on working with the regulators and other key groups to progress the potential COVID-19 treatment as rapidly as possible.
The trials showed that the average time coronavirus patients spent in hospital was reduced by a third, for those receiving the new drug down from an average of nine days to six days.
The double-blind trial involved 101 volunteers who had been admitted for treatment at nine UK hospitals for COVID-19 infections. Half of the participants were given the drug, the other half got placebo an inactive substance.
The results, published by the company under its stock market obligations, have not been published in a peer-reviewed journal as yet.
"The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lungs' immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus, said Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Trial Chief Investigator.
Professor Stephen Holgate, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton and Co-Founder of Synairgen, added, recognising that SARS-CoV-2 is known to have evolved to evade the initial antiviral response of the lung, our inhaled treatment of giving high local concentrations of interferon beta, a naturally occurring antiviral protein, restores the lung's ability to neutralise the virus, or any mutation of the virus or co-infection with another respiratory virus such as influenza orV, as could be encountered in the winter if there is a resurgence of COVID-19.
Synairgen's drug trial was the template for the Accord programme, a fast-track clinical trial scheme set up by the UK government in April to accelerate the development of new drugs for patients with COVID-19.
The team believes the drug could be even more effective at the early stages of infection.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Kolkata Port: Decline in number of voters during SIR brings in uncertainty in TMC bastion
Kolkata (PTI): A sharp decline in the number of voters following the Special Intensive Revision (SIR) of electoral rolls has injected an element of uncertainty into the Kolkata Port Assembly constituency, considered a safe seat for the ruling Trinamool Congress (TMC).
The electorate in the south Kolkata constituency has dropped from 2.36 lakh in the 2021 Assembly polls to around 1.75 lakh, a fall of nearly 26 per cent, prompting political parties to closely assess its potential impact on the April 29 polling.
The TMC re-nominated senior minister and Kolkata Mayor Firhad Hakim, who has held the seat for two consecutive terms, while the BJP fielded Rakesh Singh. The Congress nominated Aquib Gulzar, and the CPI(M) put up Faiyaz Ahmad Khan, making it a four-cornered contest.
Kolkata Port, part of the Kolkata Dakshin parliamentary constituency, comprises dock areas, old business districts and densely populated neighbourhoods. Muslim voters form a significant segment of the electorate, alongside traders, transport workers and working-class Hindu families.
The reduction in voter numbers has prompted party workers across formations to scrutinise the revised rolls booth-wise to identify deletions and assess whether specific localities have been affected.
Singh’s candidature has added a twist to the contest. He had earlier contested against Hakim as a Congress candidate but is now in the fray on a BJP ticket.
Hakim won the seat in 2016 by 26,548 votes, defeating Singh, and increased his margin significantly to 68,554 votes in 2021, polling over one lakh votes.
While the TMC has expressed confidence in retaining the seat, opposition parties have raised concerns over the voter list revision, alleging that names of genuine voters have been removed.
“People here know who has stood by them. Elections are decided by trust,” Hakim told PTI during a campaign event.
Singh claimed several residents had complained about missing names in the rolls, stressing the need for transparency. The CPI(M) nominee also said voters in several areas had raised similar concerns.
The constituency has remained a difficult terrain for the opposition in recent elections.
Civic issues such as sanitation, traffic congestion and declining business activity in traditional markets also feature in the campaign in the constituency, though the revised voter list has emerged as a key talking point.
Polling in the constituency will be held in the second phase on April 29, with counting scheduled for May 4.
